Co-occurrence Analysis
190 gene-pair Fisher's exact tests, Benjamini-Hochberg FDR, quintuple search
Gene Pairs Tested
190
Significant (BH)
145
p<0.05 after correction
Mutual Exclusions
30
Strongest
FLT3+NPM1
O/E = 9.24
Quintuple Frequency
< 1 in 2,889
Exact 95% bound from 0 of 8,655 patients; no point estimate
Co-occurrence Heatmap
Source: Fisher's exact test
31
[31] C 2013
Mutational landscape and significance across 12 major cancer types. Nature (2013)
, Benjamini-Hochberg FDR correction.
GENIE v19.0 17[17] Consortium 2017
AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov (2017)
, 21,017 myeloid samples
(sample level; selected by cancer-type keywords with hypermutation cut-off 40, an older filter than the
21,017-sample OncoTree cohort used elsewhere).
Exclusion means O/E below 1 in the same two-sided Fisher's exact test; the DISCOVER test
30[30] S 2016
A novel independence test for somatic alterations in cancer shows that biology drives mutual exclusivity but chance explains most co-occurrence. Genome Biol (2016)
, which allows mutation rates to vary between samples, was not applied here.
Color scale: log2(O/E). Blue = mutual exclusion, red = co-occurrence.
Five-gene Co-mutation Landscape (GENIE v19.0 OncoPrint)
Figure: GENIE v19.0 myeloid patients with all five genes on the
sequencing panel (8,655; samples merged per patient; myeloid OncoTree, coding variants only,
hypermutation filter). Each column is one patient with coding mutations in at least 3 of DNMT3A,
IDH2, SETBP1, PTPN11, EZH2 (62 patients: 60 with three genes, 2 with four, 0 with all five).
Gene level, not the exact variants. Right: percentage of the 8,655 patients with a coding
mutation in the gene. Source: oncoprint_matrix.json (syn72382128).
Top Co-occurrences (sample level)
| Gene Pair | Observed (samples) | Expected (samples) | O/E | p-value | BH q-value | Direction |
|---|---|---|---|---|---|---|
| FLT3 + NPM1 | 424 | 45.9 | 9.24 | < 1e-300 | < 1e-300 | Co-occurring |
| ASXL1 + SRSF2 | 737 | 228.4 | 3.23 | 7.51e-229 | 7.13e-227 | Co-occurring |
| TET2 + SRSF2 | 755 | 248.3 | 3.04 | 2.42e-217 | 1.53e-215 | Co-occurring |
| SRSF2 + RUNX1 | 561 | 153.2 | 3.66 | 6.00e-194 | 2.85e-192 | Co-occurring |
| ASXL1 + RUNX1 | 705 | 236.8 | 2.98 | 1.51e-191 | 5.74e-190 | Co-occurring |
| ASXL1 + EZH2 | 396 | 93.9 | 4.22 | 2.84e-167 | 8.98e-166 | Co-occurring |
| DNMT3A + NPM1 | 443 | 117.6 | 3.77 | 4.01e-163 | 1.09e-161 | Co-occurring |
| SRSF2 + IDH2 | 379 | 86.8 | 4.37 | 1.49e-155 | 3.53e-154 | Co-occurring |
| ASXL1 + SETBP1 | 289 | 57.0 | 5.07 | 7.92e-152 | 1.67e-150 | Co-occurring |
| ASXL1 + STAG2 | 344 | 79.1 | 4.35 | 3.80e-151 | 7.21e-150 | Co-occurring |
| SRSF2 + STAG2 | 259 | 48.9 | 5.29 | 1.03e-126 | 1.78e-125 | Co-occurring |
| RUNX1 + EZH2 | 277 | 63.0 | 4.40 | 1.51e-111 | 2.39e-110 | Co-occurring |
| TET2 + ASXL1 | 768 | 387.7 | 1.98 | 8.07e-95 | 1.18e-93 | Co-occurring |
| DNMT3A + FLT3 | 396 | 139.9 | 2.83 | 2.79e-94 | 3.79e-93 | Co-occurring |
| RUNX1 + BCOR | 240 | 57.5 | 4.17 | 2.54e-90 | 3.21e-89 | Co-occurring |
SETBP1 Partnerships (patient level)
| Partner | Co-mutated (patients) | Expected (patients) | O/E | p-value | BH q-value | Direction |
|---|---|---|---|---|---|---|
| ASXL1 | 145 | 31.1 | 4.67 | 4.40e-71 | 1.45e-69 | Co-occurring |
| SRSF2 | 79 | 21.1 | 3.73 | 6.37e-27 | 1.05e-25 | Co-occurring |
| CBL | 32 | 6.6 | 4.85 | 7.09e-14 | 7.80e-13 | Co-occurring |
| CSF3R | 18 | 1.8 | 10.00 | 1.10e-13 | 9.08e-13 | Co-occurring |
| EZH2 | 36 | 8.8 | 4.07 | 3.80e-13 | 2.51e-12 | Co-occurring |
| U2AF1 | 39 | 11.3 | 3.46 | 5.75e-12 | 3.16e-11 | Co-occurring |
| RUNX1 | 39 | 20.0 | 1.95 | 4.18e-5 | 1.97e-4 | Co-occurring |
| NRAS | 29 | 13.3 | 2.19 | 6.92e-5 | 2.86e-4 | Co-occurring |
| JAK2 | 14 | 33.2 | 0.42 | 8.32e-5 | 3.05e-4 | Exclusive |
| NPM1 Depleted | 2 | 12.6 | 0.16 | 3.55e-4 | 0.0012 | Exclusive |
| PTPN11 | 15 | 6.0 | 2.51 | 9.60e-4 | 0.0029 | Co-occurring |
| GATA2 | 11 | 4.3 | 2.54 | 0.0041 | 0.0113 | Co-occurring |
| IDH1 Depleted | 1 | 7.8 | 0.13 | 0.0051 | 0.0130 | Exclusive |
| TP53 | 14 | 25.4 | 0.55 | 0.0136 | 0.0322 | Exclusive |
| SMC3 | 4 | 1.2 | 3.25 | 0.0339 | 0.0734 | Co-occurring |
| BCORL1 | 0 | 4.0 | 0.00 | 0.0356 | 0.0734 | Exclusive |
| DDX41 | 2 | 0.5 | 4.26 | 0.0786 | 0.1526 | Co-occurring |
| STAG2 | 11 | 6.6 | 1.68 | 0.1019 | 0.1867 | Co-occurring |
| SF3B1 | 8 | 13.6 | 0.59 | 0.1200 | 0.2040 | Exclusive |
| WT1 | 3 | 7.1 | 0.42 | 0.1236 | 0.2040 | Exclusive |
| CALR | 4 | 7.6 | 0.53 | 0.2578 | 0.4051 | Exclusive |
| RAD21 | 4 | 2.3 | 1.73 | 0.2946 | 0.4418 | Co-occurring |
| ZRSR2 | 6 | 4.1 | 1.45 | 0.3109 | 0.4461 | Co-occurring |
| CEBPA | 2 | 4.5 | 0.44 | 0.3318 | 0.4562 | Exclusive |
| FLT3 | 10 | 12.4 | 0.81 | 0.5562 | 0.7341 | Exclusive |
| SMC1A | 0 | 1.3 | 0.00 | 0.6386 | 0.8105 | Exclusive |
| TET2 | 34 | 36.5 | 0.93 | 0.7143 | 0.8469 | Exclusive |
| BCOR | 9 | 8.2 | 1.09 | 0.7185 | 0.8469 | Co-occurring |
| DNMT3A | 30 | 28.9 | 1.04 | 0.8398 | 0.9364 | Co-occurring |
| KRAS | 8 | 7.6 | 1.05 | 0.8512 | 0.9364 | Co-occurring |
| IDH2 | 12 | 13.1 | 0.92 | 0.8853 | 0.9424 | Exclusive |
| MPL | 3 | 3.6 | 0.84 | 1.0000 | 1.0000 | Exclusive |
| PHF6 | 5 | 5.4 | 0.93 | 1.0000 | 1.0000 | Exclusive |
IDH1 depletion (O/E=0.13) and
NPM1 depletion (O/E=0.17) stand out as the strongest
mutual exclusions with SETBP1 mutations
1
[1] R 2013
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013)
2[2] H 2013
Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013)
.
This is biologically consistent:
SETBP1-mutant clones occupy a distinct ontogenetic niche
(MDS/MPN overlap, CNL, aCML) where NPM1 mutations are rare and
IDH1 mutations preferentially co-occur with NPM1 in AML
12[12] E 2016
Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med (2016)
.
The strongest positive associations are
CSF3R (O/E=10.00, p=1.1 × 10−13)
and ASXL1 (O/E=4.67, p=4.4 × 10−71), reflecting the classical CNL/aCML genotype.
The IDH1+SETBP1 depletion (O/E=0.13) is consistent with
SETBP1's role as an epigenetic hub
3
[3] R 2018
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. Nat Commun (2018)
, where mutant SETBP1 drives
transcriptional deregulation via HCF1/KMT2A interaction and PP2A
inhibition. Redundant epigenetic disruption through IDH1-mediated DNA
hypermethylation appears to be negatively selected when SETBP1 already
provides broad chromatin remodeling. This functional overlap explains the
mutual exclusivity: clones carrying both mutations gain no additional
fitness advantage, so the combination is purged by clonal competition.
Quintuple Co-occurrence Analysis
The quadruple analysis assumed four driver mutations. With EZH2 V662A
classified Likely Pathogenic (PP3_Strong on 6/7
concordant computational predictors; EVE dissents at 0.7825,
Uncertain at its class25 calibration), this becomes
a quintuple co-occurrence
search. The exact five-variant combination has no estimable population frequency. Zero in 8,655 patients bounds it below 1 in 2,889 (95%, exact binomial).
EZH2 V662A has 0 carriers among the 20,739 GENIE v19.0
17
[17] Consortium 2017
AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov (2017)
myeloid samples whose panel covers EZH2. The variant
itself does not exist in the database, making any multi-gene search
involving this specific variant a guaranteed zero. Because that count is zero, the
frequency of all five specific variants (DNMT3A R882H + IDH2 R140Q
+ SETBP1 G870S 1[1] R 2013
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013)
2[2] H 2013
Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013)
+ PTPN11 E76Q + EZH2 V662A) in a single myeloid patient cannot be estimated under any
model: every model value depends on the number put in for that zero.
Zero in 8,655 patients bounds it below 1 in 2,889
(95%, exact binomial). A pairwise maximum-entropy (Ising) model fitted to GENIE predicts mutations in all five genes in about 1 in 25,000 myeloid patients (95% bootstrap interval 1 in 13,000 to 1 in 65,000; sampling error only). | Combination | Observed | Expected | Notes |
|---|---|---|---|
| DNMT3A p.R882H + IDH2 p.R140Q + SETBP1 p.G870S | 0 | 0.21 | No triple match in GENIE (expected count in 18,628 eligible samples) |
| DNMT3A p.R882H + IDH2 p.R140Q + PTPN11 p.E76Q | 0 | 0.02 | No triple match in GENIE (expected count in 18,644 eligible samples) |
| DNMT3A p.R882H + SETBP1 p.G870S + PTPN11 p.E76Q | 0 | 2.5e-3 | No triple match in GENIE (expected count in 19,974 eligible samples) |
| IDH2 p.R140Q + SETBP1 p.G870S + PTPN11 p.E76Q | 0 | 2.8e-3 | No triple match in GENIE (expected count in 18,625 eligible samples) |
| All four variants (original) | 0 | 1.1e-4 | Expected count in 18,625 eligible samples |
| EZH2 V662A (fifth driver) | 0 | 0 | 0/20,739 panel-eligible samples; variant absent from GENIE |
| Gene-level quintuple (any variant) | 0 | 0.0034 | Any DNMT3A+IDH2+SETBP1+PTPN11+EZH2 variant; expected count under independence. A fitted Ising model gives about 1 in 25,000 patients (0.34 expected in 8,655) |
| All five specific variants | 0 | Not estimable | 95% bound below 1 in 2,889 (0 of 8,655 patients, exact binomial) |
Source: Expected values are simple products of
frequencies under independence, without the DISCOVER correction for varying mutation rates 30
[30] S 2016
A novel independence test for somatic alterations in cancer shows that biology drives mutual exclusivity but chance explains most co-occurrence. Genome Biol (2016)
:
P(quint) = P(DNMT3A R882H) x P(IDH2 R140Q) x P(SETBP1 G870S) x
P(PTPN11 E76Q) x P(EZH2 V662A).
Individual variant frequencies from GENIE v19.0
17[17] Consortium 2017
AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov (2017)
myeloid panel-eligible cohort
(N=21,017 myeloid,
N=18,625 panel-eligible for original four).
EZH2 V662A frequency = 0/20,739 panel-eligible samples.
Gene-level quintuple uses gene-level (any coding variant) frequencies.
The five-variant row shows the exact 95% bound instead of an expected value, because
EZH2 V662A has 0 carriers; bound and Ising model from rarity-reanalysis.json.
References
- Piazza R et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet (2013). PubMed
- Makishima H et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet (2013). PubMed
- AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discov (2017). DOI
- Kandoth C et al. Mutational landscape and significance across 12 major cancer types. Nature (2013). PubMed
- Canisius S et al. A novel independence test for somatic alterations in cancer. Genome Biol (2016). DOI
- Papaemmanuil E et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med (2016). PubMed
- Piazza R et al. SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. Nat Commun (2018). PubMed